Skip to main content

Table 2 WHO – Pipeline Zika virus (ZIKV) vaccines (in preclinical development) (last updated January 2017) January 2017)

From: Zika vaccines and therapeutics: landscape analysis and challenges ahead

Platform Candidate vaccine name Developer/Collaborators Replicating virus (Yes/No) Antigen Adjuvant
Inactivated whole target organism BK1603 BIKEN No ZIKV full genome To be determined
Inactivated whole target organism   Bio-Manguinhos in house development and Sanofi Pasteur/WRAIR (discontinued in 2017) No ZIKV full genome Alum
Recombinant subunit (non- VLP)   Bio-Manguinhos partnership No ZIKV E protein Alum
Recombinant viral vector   Bio-Manguinhos/Aggeu Magalhaes (FIOCRUZ) Yes PrM/E and PrM/E/NS1 None
Live, attenuated recombinant virus   Brazilian Ministry of Health agreement with University of Texas Yes rZIKV None
     rZIKV NS1  
Inactivated whole target organism Butantan ZIKV Butantan No ZIKV full genome Alum
Live, attenuated target organism Butantan attenuated ZIKV Butantan   ZIKV full genome None
Inactivated virus + aluminum adjuvant ZIKV Emergent BioSolutions No ZIKV full genome Aluminum
Recombinant viral vector GEO-ZM05 GeoVax/University of Georgia/CDC Atlanta, US No ZIKV PrM/E + NS1 None
SAM WT GSK-NIH Yes ZIKV prM/E  
SAM CO GSK-NIH Yes ZIKV prM/E  
SAM VRC_5283 GSK-NIH Yes ZIKV prM/E  
SAM VRC_5288 GSK-NIH Yes ZIKV prM/E  
Recombinant subunit (non-VLP) ZIK-80E Hawaii Biotech, Inc. No   
Recombinant subunit VLP (non-fusion) ZIKVLP Institut Pasteur Shanghai, China No   
Recombinant viral vector NI.LV-ZIK Institut Pasteur, Paris, France No ZIKV prM/E None
Recombinant viral vector ChAdOx1-Zk Jenner Institute   ZIKV prM/E None
Inactivated whole target organism KAKETSUKEN ZIKV Kaketsuken No ZIKV full genome TBD
Inactivated whole target organism   NewLink Genetics No ZIKV prM/E + NS1 TBD
Recombinant subunit VLP (fusion)   NewLink Genetics No ZIKV prM-E TBD
Live, attenuated target organism rZIKV/D2D30 NIAID Yes ZIKV prM/E None
Live, attenuated target organism rZIKV/D4D30 NIAID Yes ZIKV prM/E None
Live, attenuated target organism rZIKVD30 NIAID Yes ZIKV full genome None
Recombinant viral vector   NIAID Yes   None
Sf9 cells/Baculo ZIKV envelope dimers (EnvD) Novavax, Inc. No ZIKV E protein Matrix M adjuvant or aluminum hydroxide
nanoDNA/ZIKA-LAMP chimera construct LAMP-ZIKA nanoDNA Pharos Biologicals No ZIKV prM/E  
Recombinant subunit (non-VLP) ZIKA recombinant Protein Sciences/Sinergium Biotech/Lab Liomont No ZIKV E protein Aluminum based
Peptide Replikins Zika Vaccine and Bocker Replikins Ltd. No Synthetic Peptides None
Recombinant viral vector Chimerivax-Zika Sanofi Pasteur   ZIKV prM/E + NS1 None
Recombinant viral vector SCV-CHIKV+ZIKV+YF Sementis Ltd. No ZIKV, yellow fever, and CHIKV surface antigens None
Recombinant viral vector SCV-CHIKV+ZIKV Sementis Ltd. No ZIKV and CHIKV surface antigens None
Recombinant viral vector SCV-ZIKV Sementis Ltd. No ZIKV surface antigens None
Inactivated whole target organism   Takeda No ZIKV full genome Alum
Subunit   Tours University No   
VLP HBV-Zika
Prime-boost   U1187 INSERM (CYROI, La Reunion)    
Live attenuated + ZIKV exosome
Inactivated whole target organism   Valneva No ZIKV full genome Aluminum hydroxide
Recombinant viral vector VXA-Zikavax Vaxart   ZIKV prM/E  
VLP VBI-2501A VBI Vaccines No ZIKV E + NS1  
DNA   WRAIR/BIDMC/Harvard No ZIKV prM/E  
Recombinant viral vector   WRAIR/BIDMC/Harvard   ZIKV prM/E  
  1. BIDMC Beth Israel Deaconess Medical Center, BIKEN Research Foundation for Microbial Diseases of Osaka University, CDC Centers for Disease Control and Prevention, CHIKV Chikungunya virus, GSK GlaxoSmithKline, LAMP loop-mediated isothermal amplification, NIH National Institutes of Health, NIAID National Institute of Allergy and Infectious Diseases, SAM self-amplifying mRNA, SCV Sementis Copenhagen vector, VLP virus-like particles, WRAIR Walter Reed Army Institute of Research, YF Yellow fever, ZIKV Zika virus